A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
|Podcasts|September 26, 2022
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
CAR T therapies are potentially revolutionizing the treatment of acute lymphoblastic leukemia (ALL).
Advertisement
This month, we spoke with Craig Freyer, PharmD, BCOP, clinical pharmacy specialist at Penn Medicine, to learn about how CAR T therapies are potentially revolutionizing the treatment of acute lymphoblastic leukemia (ALL). In addition to discussing what makes ALL treatment unique from other cancer treatments, Freyer said pharmacists have important roles to play in managing cytokine release syndrome and potential neuro-toxicities.
Advertisement
Related to this article
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
5